Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy

Journal of Thoracic Oncology

Volumn 3, Issue 6 6 SUPPL 2, 2008, Pages

  Lynch Jr , Thomas J ^a   Blumenschein Jr , George R ^b   Engelman, Jeffrey A ^a   Espinoza Delgado, Igor ^c   Govindan, Ramaswamy ^d   Hanke, Jeff ^e   Hanna, Nasser H ^f   Heymach, John V ^b   Hirsch, Fred R ^g   Janne, Pasi A ^h   Lilenbaum, Rogerio C ⁱ   Natale, Ronald B ^j   Riely, Gregory J ^k   Sequist, Lecia V ^a   Shapiro, Geoffrey I ^h   Shaw, Alice ^l   Shepherd, Frances A ^m   Socinski, Mark ⁿ   Sorensen, A Gregory ^o   Wakelee, Heather A ^p   Weitzman, Aaron ^q   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ASTRAZENECA   (United Kingdom)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ Mount Sinai Comprehensive Cancer Center   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p STANFORD CANCER INSTITUTE   (United States)

^q GENENTECH INC   (United States)

more..

Author keywords

Biopsies; EGFR; Lung cancer; Novel targets; Profiling; VEGF

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CONTRAST MEDIUM; CPG 7909; DOCETAXEL; ERLOTINIB; GEFITINIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; MELANOMA ANTIGEN 3; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; VANDETANIB; XL 647;

ANGIOGENESIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONGENITAL SKIN DISEASE; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; WILD TYPE;

EID: 44649148421     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318174e9d3     Document Type: Conference Paper

References (0)